Claims
- 1. A compound of general formula (Ia): wherein: R1 represents aryl, heteroaryl, optionally substituted alkyl, alkenyl or alkynyl where each is optionally substituted by R2, —Z2R3, —Z3H, —C(═O)—R3, —NR4—C(═Z3)—R3, —NR4—C(═O)—OR3, —NR4—SO2—R3, —SO2—NY1Y2, —NY1Y2 or —C(═Z3)—NY1Y2, or optionally substituted cycloalkyl or heterocycloalkyl where each is optionally substituted by R3, —Z2R3, —Z3H, —C(═O)—R3, —NR4—C(═Z3)—R3, —NR4—C(═O)—OR3, —NR4—SO2—R3, —SO2—NY1Y2, —NY1Y2 or —C(═Z3)—NY1Y2; R2 represents aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycloalkyl; R3 represents alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocycloalkyl or heterocycloalkylalkyl; R4 represents hydrogen or lower alkyl; R5 is a direct bond or an alkylene chain, an alkenylene chain or an alkynylene chain; R7 is hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R8 is alkyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, or alkyl substituted by aryl, an acidic functional group (or corresponding protected derivative), cycloalkyl, heteroaryl, heterocycloalkyl, —Z3H, —Z2R3, —C(═O)—NY3Y4 or —NY3Y4; R9 is hydrogen, R3 or alkyl substituted with alkoxy, cycloalkyl, hydroxy, mercapto, alkylthio or —NY3Y4; R10 is hydrogen or a group consisting amino acid side chains and corresponding protected derivatives, an acidic functional group or corresponding protected derivative, R3, —Z2R3, —C(═O)—R3, or —C(═O)—NY3Y4, or alkyl substituted by an acidic functional group or corresponding protected derivative or by R3, —Z2R3, —NY3Y4, —NH—C(═O)—R3, —C(═O)—R5—NH2, —C(═O)—Ar2—NH2, —C(═O)—R5—CO2H, or —C(═O)—NY3Y4; or R9 and R10 together with the atoms to which they attached form a 3- to 6-membered heterocycloalkyl ring; R11 is C1-6alkylene, optionally substituted by R3; R12 is alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R13 is hydrogen, or alkyl optionally substituted by aryl, an acidic functional group or corresponding protected derivative, cycloalkyl, heteroaryl, heterocycloalkyl, —Z3H, —Z2R3, —C(═O)—NY3Y4 or —NY3Y4; R16 is hydrogen, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulphinyl, alkylsulphonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulphinyl, arylsulphonyl, arylthio, carboxy, cyano, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, hydroxy, nitro, trifluoromethyl, Y1Y2N—, Y1Y2NCO—, Y1Y2NSO2—, Y1Y2N—C2-6alkylene—Z1—, alkylC(═O)—Y1N—, alkylSO2—Y1N— or alkyl optionally substituted with aryl, heteroaryl, hydroxy, or Y1Y2N—Ar1 is pyridyl; Ar2 is arylene or heteroaryldiyl; L2 represents: (i) a direct bond; (ii) an alkylene, alkenylene, alkynylene, cycloalkenylene, heteroaryldiyl, hetrocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group (or corresponding protected derivative), R3, —Z3H, —Z2R8, —C(═O)—R3, —N(R7)—C(═O)—R8, —N(R7)—C(═O)—OR8, —N(R7)—C(═O)—NR4R8, —N(R7)—SO2—R8, —NY3Y4, or —[C(═O)—N(R9)—C(R4)(R10)]p—C(═O)—NY3Y4, or by (b) alkyl substituted by an acidic functional group (or corresponding protected derivative), or by —Z3H, —Z2R3, —C(═O)—NY3Y4 or —NY3Y4; (iii) a —[C(═O)—N(R9)—C(R4)(R10)]p— linkage (iv) a —Z4—R11— linkage; (v) a —C(═O)—CH2—C(═O)— linkage; (vi) a —R11—Z4—R11— linkage; or (vii) a —L3—L4—L5— linkage; L3 represents a direct bond and L5 represents an alkylene chain, or L3 represents an alkylene chain L5 represents a direct bond or an alkylene chain; L4 represents a cycloalkylene or heterocycloalkylene linkage; X is O; Y is carboxy or an acid bioisostere; Y1 and Y2 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group—NY1Y2 may form a cyclic amine; Y3 and Y4 are independently hydrogen, alkenyl, alkyl, alkynyl, aryl, cycloalkenyl, cycloalkyl, heteroaryl, heterocycloalkyl, or alkyl substituted by alkoxy, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, hydroxy, oxo, —NY1Y2, or one or more —CO2R7 or —C(═O)—NY1Y2groups; or the group —NY3Y4 may form a 5- to 7-membered cyclic amine which (i) may be optionally substituted with one or more substituents selected from alkoxy, carboxamido, carboxy, hydroxy, oxo (or a 5-, 6- or 7-membered cyclic acetal derivative thereof) or R8; (ii) may also contain a further heteroatom selected from O, S, SO2, or NY5; and (iii) may also be fused to additional aryl, heteroaryl, heterocycloalkyl or cycloalkyl rings to form a bicyclic or tricyclic ring system; Y5 is hydrogen, alkyl, aryl, arylalkyl, —C(═O)—R12, —C(═O)—OR12 or —SO2R12; Z1 represents a direct bond, an alkylene chain or NR4, O or S(O)n; Z2is O or S(O)n; Z3is O or S; Z4 is O, S(O)n, NR13, SO2NR13, NR13C(═O), C(═O)NR13 or C(═O); and n is zero or an integer 1 or 2; p is zero or an integer 1 to 4; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs; but excluding compounds where an oxygen, nitrogen or sulphur atom is attached directly to a carbon carbon multiple bond of an alkenyl or alkynyl residue.
- 2. A compound according to claim 1 in which L2 represents:(i) a direct bond; (ii) an alkylene, alkenylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group (or corresponding protected derivative), R3, —Z3H, —Z2R8, —C(═O)—R3, —N(R7)—C(═O)—R8, —N(R7)—C(═O)—OR8, —N(R7)—C(═O)—NR4R8, —N(R7)—SO2—R8, —NY3Y4, or —[C(═O)—N(R9)—C(R4)(R10)]p—C(═O)—NY3Y4, or by (b) alkyl substituted by an acidic functional group (or corresponding protected derivative), or by —Z3H, —Z2R3, —C(═O)—NY3Y4 or —NY3Y4; (iii) a —[C(═O)—N(R9)—C(R4)(R10)]p— linkage; (iv) a —Z4—R11— linkage; (v) a —C(═O)—CH2—C(═O)— linkage; or (vi) a —R11—Z4—R11— linkage.
- 3. A compound according to claim 1 in which R1 represents optionally substituted phenyl.
- 4. A compound according to claim 1 in which Z1 represents NH.
- 5. A compound according to claim 1 in which Ar1 represents optionally substituted pyridin-2,5-diyl.
- 6. A compound according to claim 1 in which Ar1 represents unsubstituted pyridin-2,5-diyl.
- 7. A compound according to claim 1 in which L2 represents a C1-4alkylene linkage optionally substituted by C1-4alkyl, aryl, heteroaryl, —Z2R8, —N(R7)—C(═O)—R8, —N(R7)—C(═O)—OR8, —N(R7)—SO2—R8, —NY3Y4, —[C(═O)—N(R9)—C(R4)(R10)]p—C(═O)—NY3Y4 or alkyl substituted by hydroxy, —OR3, —C(═O)—OR3 or —NY3Y4.
- 8. A compound according to claim 7 in which L2 represents ethylene optionally substituted by C1-4alkyl, aryl, heteroaryl, —Z2R8, —N(R7)—C(═O)—R8, —N(R7)—C(═O)—OR8, —N(R7)—SO2—R8, —NY3Y4, —[C(═O)—N(R9)—C(R4)(R10)]p—C(═O)—NY3Y4 or alkyl substituted by hydroxy, —OR3, —C(═O)—OR3 or —NY3Y4.
- 9. A compound according to claim 8 in which L2 is a group where R15 is hydrogen or C1-4alkyl and R14 represents C1-4alkyl, or where R15 is hydrogen and R14 represents aryl, heteroaryl, —Z2R8, —N(R7)—C(═O)—R8, —N(R7)—C(═O)—OR8,—N(R7)—SO2—R8, —NY3Y4, —[C(═O)—N(R9)—C(R4)(R10)]p—C(═O)—NY3Y4 or alkyl substituted by hydroxy, —OR3, —C(═O)—OR3 or —NY3Y4.
- 10. A compound according to claim 9 in which L2 is a group where R14 represents C1-4alkyl, —Z2R8, —N(R7)—C(═O)—R8, —N(R7)—C(═O)—OR8, —N(R7)—SO2—R8, —NY3Y4, or alkyl substituted by hydroxy, —OR3, —C(═O)—OR3 or —NY3Y4.
- 11. A compound according to any claim in which Y is carboxy.
- 12. A compound according to claim 1 in which R16 represents hydrogen, C1-4 alkyl or C1-4 alkoxy.
- 13. A compound according to claim 1 in which the group is attached at the ring 6 position.
- 14. A compound according to claim 1 selected from the group consisting of:(3RS)-3-{5-[2-(2-o-tolylamino-benzoxazol-6-yl)-acetylamino]-pyrid-2-yl}-butyric acid; (3RS)-3-{5-[2-(4-methyl-2-o-tolylamino-benzoxazol-6-yl)acetylamino]pyrid-2-yl}butyric acid; (RS) 3-{5-[2-(2-phenylamino-benzoxazol-6-yl)-acetylamino]-pyridin-2-yl}-butyric acid; (RS) 3-(5-{2-[2-(2-chloro-phenylamino)-benzoxazol-6-yl]-acetylamino}-pyridin-2-yl)-butyric acid; (RS) 3-{5-[2-(2-o-tolylamino-benzoxazol-6-yl)-acetylamino]-pyridin-2-yl}-butyric acid; (RS) 3-(5-{2-[2-(2-methoxy-phenylamino)-benzoxazol-6-yl]-acetylamino}-pyridin-2-yl)-butyric acid; (RS) 3-{6-[2-(2-phenylamino-benzoxazol-6-yl)-acetylamino]-pyridin-3-yl }-butyric acid; (RS) 3-(6-{2-[2-(2-chloro-phenylamino)-benzoxazol-6-yl]-acetylamino}-pyridin-3-yl)-butyric acid; (RS) 3-{6-[2-(2-o-tolylamino-benzoxazol-6-yl)-acetylamino]-pyridin-3-yl }-butyric acid; (RS) 3-(6-{2-[2-(2-methoxy-phenylamino)-benzoxazol-6-yl]-acetylamino }-pyridin-3-yl)-butyric acid; and (RS) 3-(6-{2-[2-(3-methoxy-phenylamino)-benzoxazol-6-yl]-acetylamino}-pyridin-3-yl)-butyric acid.
- 15. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide prodrug thereof, in association with a pharmaceutically acceptable carrier or excipient.
- 16. A method for the treatment of a human or non-human animal patient suffering from, or subject to, a condition which can be ameliorated by the administration of an inhibitor of α4β1 mediated cell adhesion comprising administering to said patient an effective amount of a compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof.
- 17. A method for the treatment of a patient suffering from, or subject to, asthma comprising administering to said patient an effective amount of a compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof.
- 18. A method for the treatment of a human or non-human animal patient suffering from, or subject to, a condition which can be ameliorated by the administration of an inhibitor of α4β1 mediated cell adhesion comprising administering to said patient an effective amount of a composition according to claim 15.
- 19. A method for the treatment of a patient suffering from, or subject to, asthma comprising administering to said patient an effective amount of a composition according to claim 15.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9908355 |
Apr 1999 |
GB |
|
Parent Case Info
This application is a continuation of PCT/GB00/01393, filed Apr. 12, 2000, which claims priority from GB Application No. 9908355.2, filed Apr. 12, 1999, and U.S. Provisional Application No. 60/141,470, filed Jun. 29, 1999.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
20020137782 |
Clark et al. |
Sep 2002 |
A1 |
Foreign Referenced Citations (2)
Number |
Date |
Country |
WO 9708145 |
Mar 1997 |
WO |
WO 9952896 |
Oct 1999 |
WO |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/141470 |
Jun 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/GB00/01393 |
Apr 2000 |
US |
Child |
09/975721 |
|
US |